Third Arc Bio vs Earendil Labs
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $52M Series A extension (Feb 2026) from a16z as new investor — total $217M. ARC101 (bispecific T cell engager, CLDN6+) in Phase 1 solid tumors. Platform spans oncology and autoimmune.
About
Third Arc Bio raised a $52 million Series A extension in February 2026 with Andreessen Horowitz as a new investor, building on its prior $165 million Series A to reach $217 million in total financing. The company develops multifunctional antibodies — protein therapeutics that combine multiple mechanisms of action in a single molecule — with its lead program ARC101 being a bispecific T cell engager targeting CLDN6 in solid tumors, currently in Phase 1 clinical trials.
Full-stack AI biologics company raised $787M in Mar 2026 backed by Sanofi, Pfizer/Hillhouse, and DST Global; $2.56B Sanofi collaboration signed Jan 2026; platform generates 40+ AI-designed protein therapeutics across multiple therapeutic areas.
About
Earendil Labs is a full-stack AI biologics company that uses a proprietary AI platform to design protein therapeutics at scale. The company secured $787 million in financing in March 2026, backed by Sanofi, the Pfizer-Hillhouse Biotech Fund, Dimension Capital, and DST Global — one of the largest AI drug discovery raises in the industry's history.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.